---
title: "China Medical System Unit Dermavon Enrolls First Patient in China Phase III Vitiligo Drug Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306116011.md"
description: "China Medical System subsidiary Dermavon enrolled the first patient in its Phase III trial for povorcitinib, an oral JAK1 inhibitor, to treat non-segmental vitiligo. The study involves approximately 174 adults across 44 Chinese centers. The drug has received breakthrough therapy designation from China's regulator. Additionally, Dermavon is pursuing a separate listing on the Hong Kong Stock Exchange Main Board."
datetime: "2026-11-19T12:09:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306116011.md)
  - [en](https://longbridge.com/en/news/306116011.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306116011.md)
generator: "portal-rs"
---

# China Medical System Unit Dermavon Enrolls First Patient in China Phase III Vitiligo Drug Trial

-   China Medical System subsidiary Dermavon enrolled the first patient in its Chinese Phase III povorcitinib vitiligo trial on Nov. 19, 2026. \* The trial targets approximately 174 adults with non-segmental vitiligo across about 44 Chinese research centers to evaluate efficacy and safety. \* The oral JAK1 inhibitor has received breakthrough therapy designation from China’s drug regulator. \* Dermavon is seeking a separate listing on the Hong Kong Stock Exchange’s Main Board. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190704PRIMZONEFULLFEED9881254) on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [00867.HK](https://longbridge.com/en/quote/00867.HK.md)

## Related News & Research

- [Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and Manageable](https://longbridge.com/en/news/306083646.md)
- [CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment](https://longbridge.com/en/news/304245326.md)
- [China Medical System Unit Rxilient Medical Wins Singapore Approval for Vitiligo Cream](https://longbridge.com/en/news/304176029.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**